|

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

RECRUITINGN/ASponsored by Blokhin's Russian Cancer Research Center
Actively Recruiting
PhaseN/A
SponsorBlokhin's Russian Cancer Research Center
Started2025-12
Est. completion2026-05
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07281001

Summary

This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Patients aged over 18 years old.
2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
3. Patients has received Trastuzumab Deruxtecan
4. Available medical history.

Exclusion Criteria:

1. Incomplete medical history.
2. Pregnancy or breast-breeding

Conditions4

Breast CancerCancerHER2-positive Breast CancerTrastuzumab Deruxtecan

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.